Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O75911

UPID:
DHRS3_HUMAN

ALTERNATIVE NAMES:
DD83.1; Retinal short-chain dehydrogenase/reductase 1; Retinol dehydrogenase 17; Short chain dehydrogenase/reductase family 16C member 1

ALTERNATIVE UPACC:
O75911; B2R7F3; Q5VUY3; Q6UY38; Q9BUC8

BACKGROUND:
The enzyme Short-chain dehydrogenase/reductase 3, also referred to as Retinol dehydrogenase 17 or Short chain dehydrogenase/reductase family 16C member 1, is pivotal in the conversion of all-trans-retinal to all-trans-retinol, utilizing NADPH. This biochemical reaction is essential for maintaining visual function and the health of photoreceptor cells.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Short-chain dehydrogenase/reductase 3 offers promising avenues for the development of novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.